Positive Reimbursement Coverage Issued for RedPath Integrated Pathology, Inc.’s PathFinderTG(R) Technology

PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc. (“RedPath”), a cancer molecular diagnostics company headquartered in Pittsburgh, PA, announced today that Highmark Medicare Services, Inc. (HMS), the contractor that administers Medicare programs for providers in Pennsylvania, New Jersey, Maryland, Delaware and the District of Columbia, has issued a positive Local Coverage Decision (LCD) for the company’s PathFinderTG Technology for pancreatic cancer, cysts, and masses.

MORE ON THIS TOPIC